Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enlivex Therapeutics Ltd (NQ: ENLV ) 1.380 -0.030 (-2.13%) Streaming Delayed Price Updated: 3:30 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Enlivex Therapeutics Ltd < Previous 1 2 Next > CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV) July 17, 2024 Via AB Newswire Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis June 24, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 June 20, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis June 17, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis June 03, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering May 29, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering May 28, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events April 29, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis April 22, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis April 16, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis April 11, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis April 11, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV March 22, 2024 Via ACCESSWIRE Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis February 26, 2024 Via ACCESSWIRE Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals February 21, 2024 Via ACCESSWIRE Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method February 07, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis January 17, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Therapeutics Ltd. (NASDAQ: ENLV) Leading the Way in Tuesday Trading Based on Percentage Gain January 02, 2024 Via Investor Brand Network Exposures COVID-19 Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis December 20, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer November 21, 2023 From MediWound Ltd. Via GlobeNewswire Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results September 11, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 07, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 August 02, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis July 31, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update June 26, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex to Present at the 2023 Jefferies Healthcare Conference June 06, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy May 31, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy May 08, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy April 19, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Appoints Andrew Singer to its Board of Directors April 17, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.